The Clinical Trial Regulation is currently being discussed. As patients, researchers, doctors, scientists and civil society representatives we would like to draw your attention not only to the dangers it encompasses but also to the opportunities it brings along.
The International Society of Drug Bulletins issued a statement today to the members of European Parlament to request:
The protection of human subjects must be upheld & citizens’ right to information must be strengthened
On 18 June 2012, the EU Commission published a draft concept paper for public consultation on the “Introduction of fees to be charged by the European Medicines Agency for pharmacovigilance”.
Send a completed application form together with:
The Committee examines applications for admission, checks that the applicant fulfils the requirements and makes a decision to grant or refuse membership. The Committee may request further information to assist it in making its decision.
All members and associate members are required to pay an annual membership fee. A member joining part way through a year will be asked to pay an apportioned part of that year's fee. There are three categories of membership fees to ensure that there is no financial barrier to membership of the society. We suggest contributions depending on the member‘s overall budget. This is not definitive but serves as a guide only. Financial constraints are not a bar to membership of ISDB. Members who cannot afford to pay even the lowest rate of £45 can apply for exemption.
(*) It is possible to apply for exemption when payment (45 €) is difficult.
ISDB has two categories of members: full members who meet all membership requirements as set out in the Constitution; and associate members.
The main requirements for membership are editorial and financial independence, and the quality of the information published.
A drug bulletin is defined in the Society’s constitution as a periodical concerned with the promotion of rational drug therapy and which is published at least four times a year. At least five issues must have been published to be eligible for membership. Good-quality information is that which helps the user of the information to optimise his/her therapeutic activity in the best interests of the patient. The publication must be produced by an independent editorial team and contains no advertising relating to therapeutic or diagnostic activities. The organisational structure and financial resources must be such as to guarantee the editorial team's independence.
A full member can reproduce the ISDB logo on their publication.
Institutions or individuals sympathetic to the purposes of de Society, but not qualified to be members, may, at the absolute discretion of the Committee and on payment of the relevant subscription, be given the status of Associate Member of the Society. associate membersshall have all the rights and obligations of members except those of voting and of standing for office and use of the Society’s logo.
ISDB - International Society of Drug bullettins
Contact details:
President: president@isdbweb.org
Webmaster: maria.font@ulss20.verona.it
© 2013